Archaeal TFEα/β is a hybrid of TFIIE and the RNA polymerase III subcomplex hRPC62/39

  1. Fabian Blombach
  2. Enrico Salvadori
  3. Thomas Fouqueau
  4. Jun Yan
  5. Julia Reimann
  6. Carol Sheppard
  7. Katherine L Smollett
  8. Sonja V Albers
  9. Christopher WM Kay
  10. Konstantinos Thalassinos
  11. Finn Werner  Is a corresponding author
  1. University College London, United Kingdom
  2. Max Planck Institute for Terrestrial Microbiology, Germany

Abstract

Transcription initiation of archaeal RNA polymerase (RNAP) and eukaryotic RNAPII is assisted by conserved basal transcription factors. The eukaryotic transcription factor TFIIE consists of α and β subunits. Here we have identified and characterised the function of the TFIIEβ homologue in archaea that on the primary sequence level is related to the RNAPIII subunit hRPC39. Both archaeal TFEβ and hRPC39 harbour a cubane 4Fe-4S cluster, which is crucial for heterodimerization of TFEα/β and its engagement with the RNAP clamp. TFEα/β stabilises the preinitiation complex, enhances DNA melting, and stimulates abortive and productive transcription. These activities are strictly dependent on the β subunit and the promoter sequence. Our results suggest that archaeal TFEα/β is likely to represent the evolutionary ancestor of TFIIE-like factors in extant eukaryotes.

Article and author information

Author details

  1. Fabian Blombach

    Institute for Structural and Molecular Biology, Division of Biosciences, University College London, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  2. Enrico Salvadori

    Institute for Structural and Molecular Biology, Division of Biosciences, University College London, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  3. Thomas Fouqueau

    Institute for Structural and Molecular Biology, Division of Biosciences, University College London, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  4. Jun Yan

    Institute for Structural and Molecular Biology, Division of Biosciences, University College London, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  5. Julia Reimann

    Molecular Biology of Archaea Group, Max Planck Institute for Terrestrial Microbiology, Marburg, Germany
    Competing interests
    The authors declare that no competing interests exist.
  6. Carol Sheppard

    Institute for Structural and Molecular Biology, Division of Biosciences, University College London, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  7. Katherine L Smollett

    Institute for Structural and Molecular Biology, Division of Biosciences, University College London, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  8. Sonja V Albers

    Molecular Biology of Archaea Group, Max Planck Institute for Terrestrial Microbiology, Marburg, Germany
    Competing interests
    The authors declare that no competing interests exist.
  9. Christopher WM Kay

    Institute for Structural and Molecular Biology, Division of Biosciences, University College London, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  10. Konstantinos Thalassinos

    Institute for Structural and Molecular Biology, Division of Biosciences, University College London, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  11. Finn Werner

    Institute for Structural and Molecular Biology, Division of Biosciences, University College London, London, United Kingdom
    For correspondence
    f.werner@ucl.ac.uk
    Competing interests
    The authors declare that no competing interests exist.

Reviewing Editor

  1. Patrick Cramer, Max Planck Institute for Biophysical Chemistry, Germany

Publication history

  1. Received: April 28, 2015
  2. Accepted: June 11, 2015
  3. Accepted Manuscript published: June 12, 2015 (version 1)
  4. Version of Record published: July 8, 2015 (version 2)

Copyright

© 2015, Blombach et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,669
    Page views
  • 321
    Downloads
  • 37
    Citations

Article citation count generated by polling the highest count across the following sources: Crossref, Scopus, PubMed Central.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Fabian Blombach
  2. Enrico Salvadori
  3. Thomas Fouqueau
  4. Jun Yan
  5. Julia Reimann
  6. Carol Sheppard
  7. Katherine L Smollett
  8. Sonja V Albers
  9. Christopher WM Kay
  10. Konstantinos Thalassinos
  11. Finn Werner
(2015)
Archaeal TFEα/β is a hybrid of TFIIE and the RNA polymerase III subcomplex hRPC62/39
eLife 4:e08378.
https://doi.org/10.7554/eLife.08378
  1. Further reading

Further reading

    1. Biochemistry and Chemical Biology
    2. Structural Biology and Molecular Biophysics
    Brandon Wey-Hung Liauw et al.
    Research Article

    Activation of G protein-coupled receptors (GPCRs) is an allosteric process. It involves conformational coupling between the orthosteric ligand binding site and the G protein binding site. Factors that bind at non-cognate ligand binding sites to alter the allosteric activation process are classified as allosteric modulators and represent a promising class of therapeutics with distinct modes of binding and action. For many receptors, how modulation of signaling is represented at the structural level is unclear. Here, we developed FRET sensors to quantify receptor modulation at each of the three structural domains of metabotropic glutamate receptor 2 (mGluR2). We identified the conformational fingerprint for several allosteric modulators in live cells. This approach enabled us to derive a receptor-centric representation of allosteric modulation and to correlate structural modulation to the standard signaling modulation metrics. Single-molecule FRET analysis revealed that a NAM increases the occupancy of one of the intermediate states while a PAM increases the occupancy of the active state. Moreover, we found that the effect of allosteric modulators on the receptor dynamics is complex and depend on the orthosteric ligand. Collectively, our findings provide a structural mechanism of allosteric modulation in mGluR2 and suggest possible strategies for design of future modulators.

    1. Biochemistry and Chemical Biology
    Eugene Serebryany et al.
    Research Article Updated

    Cataract is one of the most prevalent protein aggregation disorders and still the most common cause of vision loss worldwide. The metabolically quiescent core region of the human lens lacks cellular or protein turnover; it has therefore evolved remarkable mechanisms to resist light-scattering protein aggregation for a lifetime. We now report that one such mechanism involves an unusually abundant lens metabolite, myo-inositol, suppressing aggregation of lens crystallins. We quantified aggregation suppression using our previously well-characterized in vitro aggregation assays of oxidation-mimicking human γD-crystallin variants and investigated myo-inositol’s molecular mechanism of action using solution NMR, negative-stain TEM, differential scanning fluorometry, thermal scanning Raman spectroscopy, turbidimetry in redox buffers, and free thiol quantitation. Unlike many known chemical chaperones, myo-inositol’s primary target was not the native, unfolded, or final aggregated states of the protein; rather, we propose that it was the rate-limiting bimolecular step on the aggregation pathway. Given recent metabolomic evidence that it is severely depleted in human cataractous lenses compared to age-matched controls, we suggest that maintaining or restoring healthy levels of myo-inositol in the lens may be a simple, safe, and globally accessible strategy to prevent or delay lens opacification due to age-onset cataract.